This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (10)  • Contact me when this article is cited  Related Content  • Related articles  • Similar articles in this journal  Topic Collections  • Lipids and Lipid Disorders  • Diabetes Mellitus  • Alert me on articles by topic  Social Bookmarking   What's this?

Arch Intern Med. 2006;166:715-716.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

This issue of the ARCHIVES includes a focus on fibrates, with the publication of 2 articles, one an 18-year mortality follow-up report from the Helsinki Heart Study (HHS) and the other, a report on the role of bezafibrate in preventing the progression of insulin resistance.^1-2 In an era dominated by statins (is there anything they cannot do?), it is timely to ask whatever became of the fibrates and what role, if any, they have in a statin world.

It all started with fibrates over 30 years ago. Clofibrate was the first agent to be tested in clinical trials in the 1970s designed to evaluate the effect of lowering cholesterol level on cardiac outcomes. Unfortunately, one of these trials (the World Health Organization's Cooperative Primary Prevention Trial) showed an excess risk of cancer and all-cause mortality among those receiving active treatment, and clofibrate has since been removed from the market. . . . [Full Text of this Article]

AUTHOR INFORMATION
Hanna E. Bloomfield, MD, MPH

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED ARTICLES

Attenuation of Progression of Insulin Resistance in Patients With Coronary Artery Disease by Bezafibrate
Alexander Tenenbaum, Enrique Z. Fisman, Valentina Boyko, Michal Benderly, David Tanne, Moti Haim, Zipora Matas, Michael Motro, and Solomon Behar
Arch Intern Med. 2006;166(7):737-741.
ABSTRACT | FULL TEXT  

Gemfibrozil in the Treatment of Dyslipidemia: An 18-Year Mortality Follow-up of the Helsinki Heart Study
Leena Tenkanen, Matti Mänttäri, Petri T. Kovanen, Hanna Virkkunen, and Vesa Manninen
Arch Intern Med. 2006;166(7):743-748.
ABSTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Antiplatelet Actions of Statins and Fibrates Are Mediated by PPARs
Ali et al.
Arterioscler. Thromb. Vasc. Bio. 2009;29:706-711.
ABSTRACT | FULL TEXT  

Clinical Relevance of Non-HDL Cholesterol in Patients With Diabetes
Peters
Clin. Diabetes 2008;26:3-7.
ABSTRACT | FULL TEXT  

High-Density Lipoprotein Cholesterol: An Emerging Target for Stroke Treatment
Sanossian et al.
Stroke 2007;38:1104-1109.
ABSTRACT | FULL TEXT